GlassScriptPhysician profile
John J Kudlak
NPI 1023064847
$3,159.42
in general payments reported to CMS, 2019-2025
27 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $719 · 2020: $287 · 2021: $150 · 2022: $121 · 2023: $230 · 2024: $369 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,864 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.22 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vapotherm INC | $518.51 | 2020-2022 | |
| United Therapeutics Corporation | $265.15 | 2019-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $253.92 | 2023-2025 | Smartvest |
| Zoll Respicardia, INC. | $246.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $220.32 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $218.39 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Jazz Pharmaceuticals INC. | $208.17 | 2019-2025 | |
| Axsome Therapeutics, INC. | $181.95 | 2024-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.89 | 2019-2025 | Ofev, Jascayd |
| Lilly USA, LLC | $126.84 | 2025 | Zepbound |
| Noctrix Health, INC. | $123.05 | 2025 | Nidra |
| Insmed, INC. | $116.48 | 2025 | Brinsupri, Arikayce |
| Harmony Biosciences LLC | $96.19 | 2025 | |
| Inspire Medical Systems, INC. | $87.84 | 2023 | Inspire |
| Merck Sharp & Dohme LLC | $50.89 | 2023-2024 | Zerbaxa |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $39.62 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $39.30 | 2024 | Yupelri |
| Sunovion Pharmaceuticals INC. | $30.55 | 2019 | |
| Amgen INC. | $26.05 | 2024 | Tezspire |
| Genzyme Corporation | $24.26 | 2025 | |
| Grifols USA, LLC | $23.91 | 2024 | Xembify |
| Pulmonx Corporation | $23.32 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Avadel Cns Pharmaceuticals, LLC | $23.25 | 2025 | Lumryz |
| Viatris Specialty LLC | $16.29 | 2025 | Yupelri |
| Genentech USA, INC. | $13.24 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.90 | 2020 | |
| Circassia INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kudlak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.